Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel Highlighting Durable, Differentiated Profile in Sickle Cell Disease at American Society of Hematology Annual Meeting
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology Annual Meeting
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
Acquisition of “Thompson Falls” High-Grade Antimony Project Adjacent to America’s only Antimony Smelter
Valeura Energy: Positioned for Organic Growth and Accretive M&A in Southeast Asia’s Offshore Oil Sector
